- Home
- DXR vs NSRX Comparison
DXR vs NSRX Comparison
Compare DXR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | NSRX |
|---|---|---|
| Founded | 1970 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 63.4M |
| IPO Year | N/A | 2025 |
Fundamental Metrics
Financial Performance| Metric | DXR | NSRX |
|---|---|---|
| Price | $12.80 | $5.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $25.00 | $20.50 |
| AVG Volume (30 Days) | ★ 7.4K | 6.5K |
| Earning Date | 02-27-2026 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.46 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $66,306.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.55 | $5.50 |
| 52 Week High | $14.76 | $9.99 |
Technical Indicators
Market Signals| Indicator | DXR | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 39.11 |
| Support Level | $11.87 | $5.50 |
| Resistance Level | $12.90 | $7.70 |
| Average True Range (ATR) | 0.63 | 0.43 |
| MACD | -0.22 | -0.15 |
| Stochastic Oscillator | 12.00 | 15.84 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.